
Screening New Therapeutics for the Treatment of Post Traumatic Stress DisorderAward last edited on: 11/18/19
Sponsored Program
STTRAwarding Agency
NIH : NIMHTotal Award Amount
$141,071Award Phase
1Solicitation Topic Code
-----Principal Investigator
Neal G SimonCompany Information
Azevan Pharmaceuticals Inc (AKA: Serenix Pharmaceuticals Inc)
Research Institution
Northeastern University
Phase I
Contract Number: 1R41MH093049-01A1Start Date: 6/1/11 Completed: 5/31/12
Phase I year
2011Phase I Amount
$141,071Public Health Relevance:
Project Narrative Post-traumatic Stress Disorder (PTSD) is recognized by the National Institute of Mental Health, the Department of Defense, and the Veterans' Administration as a major medical issue. Current drug therapies for PTSD rely on repurposed antidepressants that are at best only modestly effective, produce undesirable side effects, and have recognized compliance issues. A new approach to pharmacotherapy is needed for significant improvement in clinical outcomes. Arginine Vasopressin (AVP) 1a receptor antagonists represent a potential new approach for the treatment of PTSD based on clinical and preclinical observations. This proposal will use a unique predatory fear conditioning paradigm as a preclinical model to test the feasibility of using novel V1a antagonists as a potential new pharmacotherapy for PTSD.
Thesaurus Terms:
Avpr1a;Adverse Effects;Affect;Afghanistan;American;Ammon Horn;Animals;Antidepressant Agent;Antidepressant Drugs;Antidepressants;Antidepressive Agents;Antidiuretic Hormone;Antidiuretic Hormone Receptor 1a;Antidiuretic Hormones;Arginine Vasopressin Receptor 1a;Argipressin;Armed Forces Personnel;Attenuated;Brain;Clinical;Common Rat Strains;Conditioned Stimulus;Cornu Ammonis;Dod;Department Of Defense;Development;Disease;Disorder;Drug Therapy;Drugs;Encephalon;Encephalons;Exhibits;Exposure To;Fear;Feasibility Studies;Ferrets;Fright;Functional Magnetic Resonance Imaging;General Population;General Public;Gustation;Hippocampus;Hippocampus (Brain);Incidence;Iraq;Mri, Functional;Magnetic Resonance Imaging, Functional;Mammals, Rats;Medical;Medication;Memory;Military;Military Personnel;Modeling;Nimh;National Institute Of Mental Health;National Institute Of Mental Health (U.S.);Nervous System, Brain;Neuroses, Post-Traumatic;Neuroses, Posttraumatic;Outcome;Pbo;Ptsd;Patients;Pattern;Pharmaceutic Preparations;Pharmaceutical Agent;Pharmaceutical Preparations;Pharmaceuticals;Pharmacologic Substance;Pharmacological Substance;Pharmacotherapy;Phase;Placebos;Post-Traumatic Stress Disorders;Pre-Clinical Model;Preclinical Models;Rat;Rattus;Receptor Protein;Sccl Vasopressin Subtype 1a Receptor;Saccharose;Screening Procedure;Sham Treatment;Stimulus;Stress Disorders, Post-Traumatic;Stress Disorders, Posttraumatic;Sucrose;Taste;Taste Perception;Testing;Treatment Side Effects;United States Department Of Veterans Affairs;United States National Institute Of Mental Health;United States Veterans Administration;V1a Vasopressin Receptor;Vasopressin, 8-L-Arginine-;Vasopressin, Arginine;Vasopressin-Neurophysin Ii-Copeptin;Vasopressins;Veterans;Veterans Administration;Veterans Administration (U.S.);Veterans Affairs (U.S.);Abstracting;Alpha-D-Glucopyranoside, Beta-D-Fructofuranosyl;Arginine Vasopressin;Base;Beta-Hypophamine;Conditioned Fear;Disease /Disorder;Disease/Disorder;Drug /Agent;Drug/Agent;Experience;Fmri;Fear Conditioning;Functional Magnetic Resonance Imaging;Hippocampal;Innovate;Innovation;Innovative;Model;New Approaches;New Therapeutics;Next Generation Therapeutics;Novel;Novel Approaches;Novel Strategies;Novel Strategy;Novel Therapeutics;Phase 2 Study;Posttraumatic Stress Disorder;Pre-Clinical;Preclinical;Preclinical Study;Receptor;Response;Screening;Screenings;Sham Therapy;Side Effect;Therapy Adverse Effect;Traumatic Neurosis;Treatment Adverse Effect;Vasopressin Type 1a Receptor
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00